Kaiser Permanente Northern California

Does Kaiser Permanente Northern California cover Wegovy?

Quick answer · Weight Loss

Kaiser Permanente Northern California covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher

Last verified June 5, 2026. Policy effective June 1, 2026. Source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What Kaiser Permanente Northern California requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, CVD, CAD, OSA, osteoarthritis_of_knees, PCOS, NASH_NAFLD, asthma, and COPD)
  • BMI of 27.5 or higher for patients of Asian descent
  • BMI at or above the 95th percentile for age and sex
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Weight Loss — Initial Approval: Adult (age >= 18)

All of:

  • Age >= 18 years
  • Actively enrolled in an exercise and caloric reduction program
  • No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist

Plus any one of:

  • BMI >= 30 kg/m² (general population)
  • BMI >= 27.5 kg/m² (Asian patients)
  • BMI >= 27 kg/m² AND at least one weight-related comorbidity (HTN, T2DM, dyslipidemia, CVD, CAD, sleep apnea, osteoarthritis of knees, PCOS, NASH/NAFLD, asthma, or COPD) (general population)
  • BMI >= 25 kg/m² AND at least one weight-related comorbidity (Asian patients)

Weight Loss — Initial Approval: Adolescent (age 12–17)

All of:

  • Age 12 to 17 years
  • Initial BMI >= 95th percentile for age and sex
  • Actively enrolled in an exercise and caloric reduction program
  • No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist

Weight Loss — Renewal: Adult (age >= 18)

All of:

  • No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist
  • Baseline BMI eligibility re-confirmed (same thresholds as initial criteria)
  • Achieved or maintained at least 5% weight loss of baseline body weight

Weight Loss — Renewal: Adolescent (age 12–17)

All of:

  • Age 12 to 17 years
  • No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist
  • Achieved or maintained at least 5% reduction of baseline BMI

Documentation to bring

  • Documentation of patient age
  • Baseline BMI documentation: >= 30 kg/m² (general adult), or >= 27.5 kg/m² (Asian adult), or >= 27 kg/m² with qualifying comorbidity (general adult), or >= 25 kg/m² with qualifying comorbidity (Asian adult), or >= 95th percentile for age/sex (adolescents 12–17)
  • Documentation of at least one weight-related comorbidity if using lower BMI threshold (HTN, T2DM, dyslipidemia, CVD, CAD, sleep apnea, osteoarthritis of knees, PCOS, NASH/NAFLD, asthma, or COPD)
  • Attestation of active enrollment in an exercise and caloric reduction program
  • Confirmation of no concurrent GLP-1 receptor agonist or GLP-1/GIP receptor agonist use
  • For renewal: documentation of >= 5% weight loss from baseline body weight (adults) or >= 5% BMI reduction from baseline (adolescents 12–17)

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, at least 5% reduction in BMI, and Renewal requires: (1) no concurrent GLP-1 or GLP-1/GIP agonist; (2) for adults (>=18): re-verification of baseline BMI eligibility criteria AND at least 5% weight loss of baseline body weight achieved or maintained; (3) for adolescents (12–17): at least 5% reduction of baseline BMI achieved or maintained. Note: the 5% threshold for adults is 5% of baseline body weight; for adolescents it is 5% of baseline BMI. Active lifestyle program enrollment is NOT explicitly re-verified at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist (liraglutide, exenatide, semaglutide other products) or GLP-1/GIP receptor agonist (tirzepatide products)

Policy note: The weight loss indication covers both adults (age >= 18) and adolescents (age 12–17). For Asian adults, bmi_min_asian = 27.5 kg/m² (no comorbidity required) or 25 kg/m² with comorbidity. For renewal, adults must re-verify both BMI eligibility AND 5% weight loss; adolescents only need 5% BMI reduction. The continuation_weight_loss_percent (5%) and continuation_bmi_reduction_percent (5%) reflect different metrics: 5% body weight for adults, 5% of baseline BMI for adolescents. Pregnancy/Type 1 diabetes/bariatric surgery exclusions are not explicitly stated in this document but are standard; marked false here since not explicitly documented.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf

Wegovy for Heart Disease Risk Reduction

What Kaiser Permanente Northern California requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 27 or higher
  • BMI of 25 or higher for patients of Asian descent
  • Established cardiovascular disease (prior_MI, prior_stroke_ischemic, prior_stroke_hemorrhagic, carotid_artery_stenosis_50pct, symptomatic_PAD_with_ABI_less_than_0.85, peripheral_arterial_revascularization, and amputation_due_to_atherosclerotic_disease)
  • On guideline-directed medical therapy (antiplatelet (aspirin, clopidogrel, ticagrelor, aspirin-dipyridamole), statin (HMG-CoA reductase inhibitor), and blood pressure medication (ACEi, ARB, or beta blocker))

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction — Initial Approval

All of:

  • Age >= 18 years
  • BMI >= 27 kg/m² (or >= 25 kg/m² if Asian)
  • Established cardiovascular disease (prior MI, prior stroke [ischemic or hemorrhagic], carotid artery stenosis ≥50%, or symptomatic PAD with ABI <0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • History of and continued use of, or contraindication to, ALL GDMT: antiplatelet agent (unless history of hemorrhagic stroke), statin, and blood pressure medication (ACEi, ARB, or beta blocker)
  • Used in combination with reduced calorie diet and increased physical activity
  • No concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist

Documentation to bring

  • Documentation of age >= 18 years
  • Baseline BMI documentation (>= 27 kg/m² general, or >= 25 kg/m² for Asian patients)
  • Documentation of qualifying established CVD event (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD with ABI <0.85 at rest, peripheral arterial revascularization, or amputation due to atherosclerotic disease)
  • Documentation of current GDMT use or clinical reason GDMT is contraindicated: antiplatelet agent, statin, and blood pressure medication (ACEi, ARB, or beta blocker)
  • Documentation that Wegovy will be used with reduced calorie diet and increased physical activity
  • Confirmation of no concurrent GLP-1 receptor agonist or GLP-1/GIP receptor agonist use

Approval and renewal

  • To renew, the plan looks for Renewal requires: (1) confirmed cardiovascular disease (prior MI, prior stroke, carotid artery stenosis ≥50%, or symptomatic PAD); (2) continued use with reduced calorie diet and increased physical activity; (3) no concurrent GLP-1 or GLP-1/GIP agonist; (4) continued history of use or contraindication to GDMT (antiplatelet, statin, blood pressure medication). BMI threshold and age are NOT re-verified at renewal.

Not covered when

  • Concurrent use of another GLP-1 receptor agonist (liraglutide, exenatide, semaglutide other products) or GLP-1/GIP receptor agonist (tirzepatide products)

Policy note: GDMT antiplatelet requirement has an exception: if the patient has a history of hemorrhagic stroke, antiplatelet is not required. At renewal, the BMI threshold is not re-verified — only CV disease confirmation, GDMT, diet/activity, and no concurrent GLP-1 are checked.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf

Wegovy for Liver Disease (MASH)

What Kaiser Permanente Northern California requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy, FibroScan_VCTE, and ELF_test, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH — Initial Approval

All of:

  • Age >= 18 years
  • Diagnosis of noncirrhotic MASH/NASH
  • Therapy prescribed by or in consultation with a hepatologist, gastroenterologist, or endocrinologist
  • Patient is enrolled in or has completed a lifestyle intervention (dietary, exercise, psychology)
  • Biopsy or non-invasive test (elastography or ELF testing) within the past 12 months demonstrating liver fibrosis stage 2 or 3
  • No concurrent use of Rezdiffra (resmetirom), another GLP-1 receptor agonist, or GLP-1/GIP receptor agonist

Documentation to bring

  • Documentation of age >= 18 years
  • Diagnosis of noncirrhotic MASH/NASH
  • Prescriber attestation or consultation note from hepatologist, gastroenterologist, or endocrinologist
  • Documentation of enrollment in or completion of a lifestyle intervention program (dietary, exercise, or psychology-based)
  • Liver biopsy or non-invasive test result (elastography/FibroScan or ELF blood test) within the past 12 months demonstrating fibrosis stage F2 or F3
  • Confirmation of no concurrent use of Rezdiffra (resmetirom), GLP-1 receptor agonist, or GLP-1/GIP receptor agonist

Approval and renewal

  • To renew, the plan looks for Renewal requires: (1) disease is stable or improved from baseline; (2) no concurrent use of Rezdiffra, GLP-1 agonist, or GLP-1/GIP agonist; (3) biopsy or non-invasive test (elastography or ELF) demonstrating fibrosis stage 2 or 3 — note the renewal fibrosis test does NOT specify a 12-month lookback (only the initial criteria do). Specialist prescribing/consultation and lifestyle program enrollment are NOT re-verified at renewal.

Not covered when

  • Cirrhotic liver disease (noncirrhotic MASH/NASH only)
  • Concurrent use of Rezdiffra (resmetirom)
  • Concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist (tirzepatide products)

Policy note: Fibrosis must be stage 2 or 3 (F2–F3). The policy explicitly requires 'noncirrhotic' MASH/NASH, excluding cirrhotic patients. At renewal, the 12-month lookback on the fibrosis test is not explicitly re-stated; renewal only requires evidence of fibrosis stage 2 or 3 without a specified timeframe. The mash_confirmation_methods list is inferred from the document's examples: 'elastography' maps to FibroScan_VCTE and 'Enhanced Liver Fibrosis [ELF] testing' maps to ELF_test; liver biopsy is also explicitly listed.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf

Why Wegovy requests get denied by Kaiser Permanente Northern California

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Prescriber isn't the specialist the plan requires.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Kaiser Permanente Northern California cover Wegovy?
Kaiser Permanente Northern California covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance.
What BMI do you need for Wegovy under Kaiser Permanente Northern California?
For weight loss on Employer / Commercial Insurance plans, Kaiser Permanente Northern California requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
What does Kaiser Permanente Northern California require to renew Wegovy?
At least 5% weight loss from the starting weight, at least 5% reduction in BMI, and Renewal requires: (1) no concurrent GLP-1 or GLP-1/GIP agonist; (2) for adults (>=18): re-verification of baseline BMI eligibility criteria AND at least 5% weight loss of baseline body weight achieved or maintained; (3) for adolescents (12–17): at least 5% reduction of baseline BMI achieved or maintained. Note: the 5% threshold for adults is 5% of baseline body weight; for adolescents it is 5% of baseline BMI. Active lifestyle program enrollment is NOT explicitly re-verified at renewal.
How current is this information?
This page reflects Kaiser Permanente Northern California's written policy as of June 1, 2026, last verified against the source document on June 5, 2026.

Other medications under Kaiser Permanente Northern California

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Kaiser Permanente Northern California's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.